How to Talk to Patients About Their Wounds: Tips for Building Trust and Compliance

Summary: Published by Wound Care Professionals on December 2, 2025, this four-minute practice article addresses a frequently underemphasized dimension of wound management: the clinician-patient communication relationship. The piece opens with a striking statistic — research suggests that up to 50% of chronic wound care plans are not followed as prescribed, most commonly because of patient fear, misunderstanding, or insufficient trust in the care team. The author, Nancy Morgan, frames wound care communication not simply as information transfer, but as a two-way dialogue that builds partnership and forms the foundation for long-term compliance. The article outlines five actionable strategies. First, setting a warm and non-judgmental tone early — acknowledging the emotional burden of chronic wounds before diving into clinical details. Second, balancing accessibility with respect: avoiding oversimplification while still translating clinical terminology into plain-language explanations, with visuals of healing stage diagrams recommended where available. Third, involving patients in goal-setting by asking what aspects of the care plan may be difficult to follow in their daily routine — creating shared ownership of the wound care process. Fourth, explaining healing progress honestly and managing expectations around the nonlinear nature of wound repair, including the inflammatory, proliferative, and maturation phases, and using photos or measurements to make progress visible and motivating. Fifth, educating for long-term compliance beyond the immediate wound — including dietary guidance, hygiene, footwear for diabetic patients, and links to community support resources. The article is primarily directed at nurses, therapists, physicians, and home health providers, and is published as part of Wound Care Professionals’ broader educational and certification program portfolio.

Key Highlights:

• Up to 50% of chronic wound care plans are not followed as prescribed — most commonly due to fear, misunderstanding, or low trust in the care team
• Five strategies: (1) non-judgmental tone-setting; (2) plain-language explanation without condescension; (3) patient involvement in goal-setting; (4) transparent healing expectation management; (5) long-term compliance education
• Clinicians advised to validate the emotional impact of wounds before presenting clinical information — particularly important for patients experiencing shame, anxiety, or grief about their wound
• Wound photographs with patient consent recommended as motivational progress-tracking tools — transforming subjective improvement into visible, measurable progress
• Long-term compliance framing: wound care as a lifestyle shift requiring ongoing patient education on prevention, nutrition, hygiene, and footwear
• Applies across all care settings: hospital inpatient, outpatient wound clinic, home health, and long-term care — relevant to any clinician managing chronic or recurring wounds

Read full article

Keywords: wound care patient communication, wound care compliance, patient education wound care, chronic wound adherence, wound care trust building, wound care nurse communication

Nancy Morgan

of Detecting Bacterial Burden in Surgical Site Wounds by 11-Fold

Authors Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change
Contemporary Paradigms of Post-Surgical Wound Management

Collagen-Alginate Dressing Enhances Healing and Quality of Life in Venous Leg Ulcer Patients

An observational study published in Wound Management & Prevention evaluated the efficacy and safety of a native bovine collagen-alginate dressing (Cutimed® Epiona®) in treating non-healing venous leg ulcers (VLUs). Conducted at the Northwell Health System Comprehensive Wound Care Healing Center and Hyperbarics in New York, the study involved 60 patients over a four-week period. The research aimed to assess wound area reduction, pain management, and improvements in wound-related quality of life (QoL).:contentReference[oaicite:7]{index=7}

Key Highlights:

• Significant Wound Area Reduction: The mean wound area decreased from 17.8 ± 11.2 cm² to 11.4 ± 9.0 cm², with four patients achieving complete wound closure within the study period. :contentReference[oaicite:10]{index=10}
• Improved Pain Management: Patients reported decreased wound pain after two weeks of treatment, accompanied by a reduction in analgesic intake. :contentReference[oaicite:13]{index=13}
• Enhanced Quality of Life: Assessments using the Wound-QoL-17 questionnaire indicated significant improvements in patients’ wound-related QoL, correlating with the observed wound area reduction. :contentReference[oaicite:16]{index=16}

The study concluded that the collagen-alginate dressing is a safe and effective adjunct to standard wound care practices, promoting healing and improving patient outcomes in cases of hard-to-heal VLUs. Healthcare professionals rated the dressing’s performance as “very good” or “good,” and patients reported high levels of comfort during use. :contentReference[oaicite:21]{index=21}

Read the full article on the Wound Management & Prevention website.

Keywords:
venous leg ulcer,
collagen-alginate dressing,
wound healing,
Alisha Oropallo,
Amit S. Rao,
Sally Kaplan,
Farisha Baksh,
Christina Del Pin

Redefining Wound Healing: Point‑of‑Care Near‑Infrared Spectroscopy

A feasibility study by Andersen et al., published in *Advances in Skin & Wound Care* (May 2024), evaluated a portable, non-contact Near‑Infrared (NIR) imaging device (Snapshot NIR) to objectively assess wound healing progress. :contentReference[oaicite:1]{index=1}

Key Highlights:

• Objective Healing Metric: The device measures tissue oxygen saturation (StO₂) up to 2–3 mm beneath the wound surface, offering physiological data beyond visual inspection. :contentReference[oaicite:2]{index=2}
• Healing Delays Uncovered: In a cohort of 15 patients with lower extremity wounds, complete StO₂ normalization occurred an average of 13.5 days (median 12, range 0–35) after visual re-epithelialization. :contentReference[oaicite:3]{index=3}
• Guiding Clinical Decisions: By identifying continued physiological healing beneath intact epithelium, Clinicians can better determine safe timing for removing protective dressings and advising gradual return to full activity. :contentReference[oaicite:4]{index=4}
• Feasibility for Practice: The point‑of‑care, non-contact NIR tool enables repeatable, objective monitoring and may reduce wound recurrence risk by informing return-to-activity timelines. :contentReference[oaicite:5]{index=5}

This NIRS-based imaging approach redefines “healed” wounds by adding depth‑resolved physiological insight, helping clinicians tailor dressing changes and promote safer patient recovery.

Read the full study in Advances in Skin & Wound Care.

Keywords:
near-infrared spectroscopy,
Snapshot NIR,
tissue oxygenation,
wound assessment,
wound recurrence

Advances in Multifunctional Hydrogels for Wound Healing

A comprehensive review published in the *International Journal of Nanomedicine* explores the emerging role of multifunctional hydrogels in wound management—especially for chronic wounds such as diabetic foot ulcers. These hydrogels are designed not just to maintain a moist environment but to actively participate in different stages of the healing process.

Key Insights:

• Hydrogel Benefits: Hydrogels are biocompatible, water-rich materials that support wound hydration, absorb exudate, reduce pain, and allow for close contact with irregular wound surfaces. They can also serve as delivery vehicles for drugs, growth factors, or cells.
• Multi-Stage Action: Advanced hydrogels are now being engineered to address specific wound-healing phases—such as controlling bleeding, reducing infection, modulating inflammation, and encouraging angiogenesis and tissue regeneration.
• Smart Materials: Some hydrogels respond to environmental stimuli like pH, temperature, glucose levels, or oxidative stress. These “smart” systems can release active compounds only when needed, reducing dosing errors and improving treatment outcomes.
• Antimicrobial & Antioxidant Functions: Silver or copper nanoparticles, along with natural or synthetic antioxidants, are being incorporated into hydrogels to prevent infection and reduce oxidative damage at the wound site.
• Pro-Angiogenic Design: Hydrogels that deliver VEGF (vascular endothelial growth factor), promote macrophage polarization, or improve blood vessel formation are gaining attention for their regenerative potential.
• Emerging Technologies: Techniques like 3D bioprinting, microneedle delivery systems, and self-healing injectable hydrogels are pushing the boundaries of design, offering new hope for hard-to-heal wounds.

Challenges: Despite their promise, the clinical translation of multifunctional hydrogels faces hurdles—such as manufacturing complexity, regulatory approval, and ensuring reproducibility and safety across diverse patient populations.

This review emphasizes the transformative potential of hydrogel-based dressings—not only as passive wound covers but as active therapeutic platforms that engage with the biology of wound healing.

Keywords:
multifunctional hydrogel,
smart hydrogel,
stimuli‑responsive dressing,
antibacterial hydrogel,
angiogenic hydrogel

Read the full review on Dovepress

Nutrition and Wound Healing: Practical Takeaways for Wound Care Practitioners

At WoundCon Spring 2025, experts Dr. Nancy Munoz and Dr. Mary Litchford emphasized the pivotal role of nutrition in wound healing. They highlighted that optimal healing is not solely reliant on topical treatments but also heavily depends on the patient’s nutritional status.

Macronutrients:

• Carbohydrates: Serve as the primary energy source, supporting cellular activities and the inflammatory response. Emphasis should be on high-fiber, complex carbohydrates like whole grains, legumes, fruits, and vegetables.
• Fats: Unsaturated fats, found in olive oil, nuts, and seeds, maintain cellular integrity and reduce inflammation. Saturated and trans fats should be minimized due to their pro-inflammatory effects.
• Proteins: Essential for tissue regeneration and immune defense. Patients may require 1.25 to 1.5 grams of protein per kilogram of body weight, increasing to 2.0 grams/kg in severe cases. Both animal-based and well-planned plant-based proteins are beneficial.

Read the full article on the WoundSource website.

Keywords:
Nutrition,
Wound Healing,
Macronutrients,
Micronutrients,
Hydration,
Nancy Munoz,
Mary Litchford

New Research in Advances in Wound Care: Emerging Evidence for Clinical Practice

Summary: Advances in Wound Care — the official journal of the Wound Healing Society and the top-ranked wound care publication by impact factor — continues to publish high-impact translational research in 2026. A newly published article (DOI: 10.1177/15347346261428561) adds to its coverage spanning acute and chronic wound management, burns, surgical wounds, and diabetic ulcers. The journal, edited by Chandan K. Sen, PhD, at Indiana University School of Medicine, serves wound care physicians, nurses, advanced practice providers, biomedical engineers, and regenerative medicine researchers. Areas of active inquiry in early 2026 include antimicrobial stewardship in chronic wound infection, skin bioengineering and tissue regeneration, real-world evidence for cellular and acellular matrix products (CAMPs), and AI-assisted wound assessment. The full text of this specific article was not publicly accessible at time of formatting; the link below will direct readers to the full content.

Key Highlights:

• Advances in Wound Care is the Wound Healing Society’s flagship journal — top-ranked by impact factor in the wound care discipline
• 2026 output reflects sustained focus on biofilm management, wound bed preparation, and real-world Medicare data informing clinical practice
• Recent studies link over-reliance on clinical signs of infection to unnecessary antibiotic use — directly relevant to current antimicrobial stewardship initiatives
• Technology coverage includes 3D wound measurement, smart dressings, and AI-assisted assessment — priorities aligned with 2026 CMS policy updates
• WHS members receive discounted access; available via institutional subscription or direct purchase through SAGE Publications
• Note: Full text of DOI 10.1177/15347346261428561 was not retrievable due to access restrictions. Readers should access the full article directly.

Read full article

Keywords: advances in wound care, Wound Healing Society, chronic wound management, wound care research, translational wound research

Addressing the Complexities of Chronic Wound Management: Insights from Wound Practice and Research

Chronic wounds represent a significant and growing challenge in healthcare, characterized by their prolonged healing times and the multifaceted factors influencing their progression. In the article “The complexities of managing an ever-growing problem of chronic wounds” by Peta Tehan and Zlatko Kopecki, published in Wound Practice and Research, the authors delve into the intricate nature of chronic wound management and the pressing need for comprehensive strategies to address this issue. :contentReference[oaicite:5]{index=5}

Key Highlights:

• Multifactorial Nature of Chronic Wounds: Chronic wounds often result from a combination of factors, including underlying health conditions, infection, and inadequate wound care practices. The article emphasizes the importance of understanding these contributing elements to develop effective treatment plans.
• Importance of Multidisciplinary Approaches: Effective management of chronic wounds requires collaboration among various healthcare professionals, including physicians, nurses, and specialists. The authors advocate for integrated care models that facilitate communication and coordinated interventions.
• Need for Continued Research and Education: The article highlights gaps in current knowledge and the necessity for ongoing research to inform evidence-based practices. Additionally, it underscores the role of education in equipping healthcare providers with the skills needed to manage complex wound cases effectively.

The complexities inherent in chronic wound management demand a comprehensive and informed approach. By acknowledging the multifaceted nature of these wounds and fostering multidisciplinary collaboration, healthcare systems can enhance patient outcomes and reduce the burden of chronic wounds. Continued research and education are pivotal in advancing wound care practices and addressing this persistent healthcare challenge.

Read the full article on the Wound Practice and Research website.

Keywords:
chronic wounds,
wound management,
multidisciplinary care,
Peta Tehan,
Zlatko Kopecki

Psychological Stress Impairs Wound Healing and Collagen Production, New Review Confirms

A recent narrative review published in *Dermatology Times* highlights the significant impact of psychological stress on delayed wound healing and impaired collagen synthesis. The review consolidates evidence from multiple preclinical and clinical studies indicating that chronic stress dysregulates immune responses and inhibits essential tissue repair mechanisms.

Key Insights:

• Delayed Healing: Psychological stress disrupts normal inflammatory signaling, impairs fibroblast migration, and reduces re-epithelialization, leading to slower wound closure.
• Reduced Collagen Production: Stress hormones such as cortisol suppress collagen synthesis and fibroblast function, weakening the structural matrix of healing tissue.
• Immune Suppression: Chronic stress diminishes neutrophil and macrophage activity, impairing microbial defense and increasing infection risk in wounds.
• Clinical Relevance: The findings emphasize the importance of holistic patient care that includes psychological support for individuals with chronic or complex wounds.

Conclusion: This review underscores a growing body of evidence linking psychological stress to impaired wound healing, suggesting that clinicians should consider mental health as part of comprehensive wound management strategies.

Keywords: psychological stress, wound healing, collagen production, cortisol, immune suppression, fibroblasts

Read the full article on Dermatology Times

Jingfang Granules Show Promise in Accelerating Diabetic Wound Healing

A recent study published in Drug Design, Development and Therapy investigates the therapeutic potential of Jingfang Granules (JFG), a traditional Chinese medicine formulation, in promoting diabetic wound healing. Utilizing a combination of network pharmacology and experimental validation, the research aims to elucidate the mechanisms by which JFG may enhance wound repair in diabetic conditions. Read the full article.

Key Highlights:

• Multi-Component Analysis: Network pharmacology identified multiple active compounds within JFG that target key proteins involved in wound healing processes, including inflammation modulation and tissue regeneration.
• Pathway Enrichment: The analysis revealed that JFG influences several critical signaling pathways, such as the PI3K-Akt and MAPK pathways, which are integral to cell proliferation and angiogenesis.
• Experimental Validation: In vivo experiments demonstrated that JFG treatment significantly accelerated wound closure in diabetic rat models, corroborating the computational predictions.
• Anti-Inflammatory Effects: JFG administration resulted in reduced expression of pro-inflammatory cytokines, suggesting its role in mitigating chronic inflammation associated with diabetic wounds.

This integrative study underscores the potential of Jingfang Granules as a complementary therapeutic approach for enhancing diabetic wound healing, warranting further clinical investigations.

Read the full article on the Dove Medical Press website.

Keywords:
Jingfang Granules,
diabetic wound healing,
network pharmacology,
traditional Chinese medicine,
PI3K-Akt pathway

Clinical Utility of the MolecuLight Point-of-Care Imaging Platform
PRESS RELEASE
February 24, 2022

Toronto, ONTARIO and Philadelphia, PENNSYLVANIA – (February 24, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of 8 Clinical Posters and a Presentations and a Hands-On Workshop at the American Professional Wound Care Association’s (APWCA) Wound Week™, held from February 24 – 27, 2022 in Philadelphia, PA. Wound Week is a leading multidisciplinary meeting of wound care professionals that presents cutting-edge clinical findings and best practices presented by its expert faculty.

“We are thrilled with the significant number of presentations and posters at Wound Week showing the impressive results derived from MolecuLight point-of-care devices,” says Anil Amlani, MolecuLight’s CEO. “The clinical insights that are informed by the MolecuLight platform span the wound care continuum, including wound cleansing and hygiene, antimicrobial stewardship, detection of wound-related cellulitis and surgical site infections. The outcomes presented in these studies illustrate the significant clinical improvements to wound care provided to clinicians by the MolecuLightplatform”.

The 8 clinical posters and the presentation featuring the MolecuLight i:X at Wound Week 2022 are as follows:

Posters by Dr. Alisha Oropallo (Northwell Comprehensive Wound Healing Center and Hyperbarics, Lake Success NY) include:

• Wound Hygiene: Which Cleansing Agents and Techniques Are Most Effective?
   Download poster
• 12-week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates
   Download poster

Posters by Dr. Charles Andersen (Vascular/Endovascular/Limb Preservation Surgery Service, Madigan Army Medical Center, Joint Base Lewis-McChord, WA) include:

• Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging
   Download poster
• Guidelines for point-of-care fluorescence imaging for detection of wound bacterial burden based on Delphi consensus
   Download poster

Posters by Dr. Thomas Serena (SerenaGroup Research Foundation, Cambridge, MA) include:

• Reliance on Clinical Signs & Symptoms of Bacterial Burden in Chronic Wounds Leads to the Misuse of Antimicrobials: Analysis of the FLAAG Clinical Trial
   Download poster
• Point-of-care fluorescence imaging enhances detection of high bacterial burden in surgical site wounds
   Download poster
• Are Semi-Quantitative Clinical Cultures Inadequate? Comparison to Quantitative Analysis of 1053 Bacterial Isolates from 350 Wounds
   Download poster
• An image is worth 10,000 microbes: How fluorescence imaging augments IWGDF criteria for detection of bacterial burden in diabetic foot ulcers
   Download poster

The Clinical Presentations citing the MolecuLight point-of-care device is:

• All That Glows is Not Good (Innovative Technologies: What’s in the Pipeline?)  by Dr. Oropallo on Sat., Feb. 26, 2022, 9:00 – 10:00 am in the Commonwealth Room

In addition to the clinical posters and presentations at Wound Week,, the MolecuLight i:X^® and DX™ imaging devices will be demonstrated at the Hands-On Workshop on Thursday, February 24^th from 1:30 pm – 5:30 pm in the Regency B Ballroom. They will also be available for demonstration in the MolecuLight booth #36 in the Exhibit Hall at the Loews, Philadelphia, PA.

About MolecuLight Inc.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X^® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement.  MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT^® codes for physician work to perform “fluorescence wound imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

For more information, contact:

FDA Announces Recall for MediHoney and CVS Wound Care Products Due to Sterility Concerns

Summary: The U.S. Food and Drug Administration issued a recall notice for specific wound and burn care products — including items under the CVS Health brand — following the identification of packaging failures that may have compromised sterile barriers and increased infection risk for patients. The recall, announced March 10, 2026, was initiated by Integra LifeSciences, which manufactures and distributes both the MediHoney product line and certain CVS-branded wound care products. Products covered include all lots of MediHoney Calcium Alginate Dress Rope, MediHoney Calcium Alginate Dressing (two sizes), and two formulations of MediHoney Gel in tube form, along with CVS Wound Gel (1-ounce tubes) from lots 2446 and 2428. Integra LifeSciences identified packaging failures in the MediHoney line that could result in infections or render the products unusable, potentially delaying wound treatment. Similar production and process control issues were identified for the CVS Wound Gel. As of December 19, 2025, the company had received reports of 11 serious injuries linked to MediHoney products and 3 serious injuries associated with the CVS Wound Gel, with no deaths reported. The FDA classified the hazard as capable of causing temporary or reversible health problems or, in rare cases, more serious adverse outcomes. Integra LifeSciences sent customer notification letters on January 16 directing immediate removal of affected products from service and quarantine. Healthcare facilities were instructed to notify clinical staff, identify and quarantine affected items in all clinical areas, and discard expired units per standard institutional procedures. Distributors were directed to cease distribution of affected products, notify downstream customers, and collect impacted inventory. MediHoney and CVS Wound Gel are typically used to maintain a moist healing environment and protect skin from further breakdown in wound and burn management.

Key Highlights:

• Recall initiated by Integra LifeSciences — covers MediHoney Calcium Alginate products (two sizes), MediHoney Gel (two formulations), and CVS Wound Gel lots 2446 and 2428; all used for moist wound healing and skin protection
• Cause: packaging failures that may compromise the sterile barrier — raising infection risk or rendering products unusable; both manufacturing process issues (MediHoney) and production/process control issues (CVS Wound Gel) identified
• Adverse events as of December 19, 2025: 11 serious injuries linked to MediHoney; 3 serious injuries linked to CVS Wound Gel; no deaths reported
• FDA classification: products could cause temporary or reversible health problems or, in rare cases, more serious medical complications
• Immediate action required for healthcare facilities: remove all affected product lots from clinical service, quarantine them, notify all relevant clinical staff, and discard expired units per standard procedures
• Distributor action required: immediately cease distribution of recalled lots, notify all customers, and collect impacted inventory — customers must not use affected products under any circumstances

Read full article

Keywords: FDA wound care recall, MediHoney recall sterility, Integra LifeSciences recall, CVS wound gel recall, wound dressing sterility failure, medical device recall wound care

Integra LifeSciences

Advancing Knowledge of Acute Cutaneous Graft-Versus-Host Disease Wound Care: A Case Study

Summary: Published in the January/February 2026 issue of the Journal of Wound, Ostomy and Continence Nursing (JWOCN, Vol. 53, No. 1, pp. 59–63; DOI: 10.1097/WON.0000000000001240), this case study addresses a wound management scenario encountered increasingly in oncology and bone marrow transplant units: acute cutaneous graft-versus-host disease (GvHD) following allogeneic hematopoietic stem cell transplantation (HSCT). Acute cutaneous GvHD is a frequent and potentially life-threatening complication of allogeneic HSCT in which donor immune cells attack the recipient’s tissues, manifesting in the skin as erythema, blistering, and epidermal sloughing that can mimic severe burn injuries. Despite its prevalence, no well-established wound management guidelines exist for this condition. The case subject, Mr. T, was a 64-year-old male with acute myeloid leukemia with myelodysplasia-related changes who received an allogeneic human leukocyte antigen-matched HSCT. Seventy-five days post-transplant, he developed extensive wounds on his upper and lower limbs, part of his chest, torso, and sacrum consistent with a grade IV stage 4 presentation — the most severe classification. Systemic management involved four sequential or overlapping lines of therapy: systemic corticosteroids, tacrolimus combined with extracorporeal photopheresis (ECP), etanercept, and ruxolitinib (a JAK inhibitor increasingly used for steroid-refractory GvHD). Throughout, topical wound management used advanced dressings incorporating soft silicone layers — selected for their atraumatic removal properties, which are particularly important in fragile GvHD-affected skin prone to mechanical disruption. Wounds resolved by day 109 post-HSCT. The authors conclude that soft silicone layer dressings represent a practical and effective component of wound care in this setting, while emphasising the need for larger-scale studies to establish definitive evidence-based recommendations.

Key Highlights:

• Clinical context: acute cutaneous GvHD is a frequent complication of allogeneic HSCT (a growing cancer treatment modality); grade IV stage 4 presentation involves extensive, severe skin wounds that closely resemble burns and lack established wound management protocols
• Patient case: 64-year-old male with AML; extensive wounds on limbs, chest, torso, and sacrum developing 75 days post-HSCT; managed across four systemic therapy lines (corticosteroids → tacrolimus + ECP → etanercept → ruxolitinib) with concurrent wound care
• Wound management approach: soft silicone layer advanced dressings selected for atraumatic removal — critical in GvHD-affected skin where mechanical disruption can worsen epithelial integrity and patient pain; full wound resolution achieved by day 109
• Ruxolitinib (JAK inhibitor): highlighted as an emerging systemic agent for steroid-refractory acute GvHD; wound teams managing oncology patients should be aware of its role and potential cutaneous response timeline
• Gap in evidence: the authors explicitly note that no well-established wound management recommendations currently exist for cutaneous GvHD; this case contributes to a limited evidence base and underscores the need for prospective, multi-patient studies
• Multidisciplinary care model: effective management required coordination between transplant medicine, dermatology, and wound/ostomy nursing — a model that may inform future guidelines for complex oncology-associated skin wounds

Read full article

Keywords: graft versus host disease wound care, allogeneic HSCT skin wound, soft silicone dressing oncology, acute GvHD skin management, ruxolitinib wound healing, oncology wound care nursing

Navigating Wound Balance: Practical Approaches for the Australian Landscape

This supplement in *Wounds International* (June 2025) reports on two Australian advisory board meetings (2024–25) that adapted the global “Wound Balance” framework for use by generalist health professionals in diverse Australian care settings.

Key Highlights:

• Wound Balance 3‑Pillars: Patient-centred care, wound‑and‑skin science, and clinical‑practice balance—forming a holistic, adaptable decision-making framework :contentReference[oaicite:1]{index=1}.
• Barriers for Generalists: Challenges include limited wound-care confidence, inconsistent terminology, lack of standardized documentation, and inadequate monitoring tools such as PROMS :contentReference[oaicite:2]{index=2}.
• Australian Context: The advisory board emphasized empathetic communication, therapeutic relationships, and the mantra “Healing starts with me” as a cultural and practical anchor :contentReference[oaicite:3]{index=3}.
• Standards Alignment: Frameworks referenced include IWII Therapeutic Wound Cleansing (2025) and Australian Wound Prevention & Management Standards, 4th Edition (2023) :contentReference[oaicite:4]{index=4}.
• Next Steps: Recommendations include generalist education modules, adoption of standardized assessment tools (e.g., QoL/PROMS, biomarker use), and integration of the framework into primary, residential, and community care :contentReference[oaicite:5]{index=5}.

This report reinforces Wound Balance as a versatile, evidence-informed framework—ready for adoption across the Australian care continuum to enhance wound outcomes and clinician confidence.

Keywords:
Wound Balance,
patient‑centred care,
PROMS,
Therapeutic Wound Cleansing,
Australian Wound Standards 2023,
generalist HCP,
Healing starts with me

Read the full supplement in Wounds International

Healing with Intelligence: SAWC 2025 Keynote Highlights Transformative Role of AI

At the 2025 Symposium on Advanced Wound Care (SAWC) Spring meeting in Grapevine, Texas, the keynote titled “Healing with Intelligence” spotlighted the transformative role of artificial intelligence (AI) in wound care. Led by Dr. Eric Lullove, Chief Medical Officer at the West Boca Center for Wound Healing, the session emphasized a paradigm shift from reactive to predictive wound management.

Dr. Lullove noted that chronic wounds, affecting over 6.5 million Americans each year, are not just local issues but markers of systemic inefficiencies. AI, he argued, can help clinicians move beyond traditional documentation and embrace smarter diagnosis, streamlined workflows, and improved clinical decision-making.

The panel covered key applications of AI in wound care, including predictive analytics, automated documentation, and real-time clinical decision support. These tools are designed to augment rather than replace clinician judgment. However, a live audience poll revealed that nearly 70% of attendees had limited exposure to AI in practice—highlighting the urgent need for education and accessible integration tools.

Challenges discussed included data security, regulatory compliance, and bias in AI models—especially those trained on narrow patient demographics. Panelists emphasized the importance of designing AI that enhances care without disrupting workflows, and the ethical responsibility to ensure fairness across diverse populations.

The session concluded with a clear call to action: wound care professionals must help lead the integration of AI, ensuring it is used not only intelligently, but humanely. The future of wound care, the panel agreed, lies in combining data-driven insights with hands-on compassion.

Read the full coverage from SAWC Spring 2025 at HMP Global Learning Network.

Cold Microwave Plasma Jets for Wound Healing: Antimicrobial Efficacy, Mechanisms and Changes in Microbial Cells

Summary: Researchers at Brno University of Technology (Czech Republic), in collaboration with partners in Prague, Brno, and Lublin (Poland), have published a comprehensive investigation of cold atmospheric plasma (CAP) as a non-thermal antimicrobial strategy for wound care applications, appearing in Scientific Reports on March 6, 2026. The study was motivated by the escalating global burden of antibiotic-resistant microorganisms and the need for effective non-antibiotic decontamination methods. Using a custom-built cold microwave plasma jet, the team demonstrated effective inactivation of four clinically relevant organisms: Staphylococcus epidermidis, Escherichia coli, Cutibacterium acnes, and Nakaseomyces glabratus (formerly Candida glabrata). A critical mechanistic finding was that reactive oxygen and nitrogen species (RONS) — not UV radiation — are primarily responsible for microbial inactivation, established through colorimetric agent experiments and enclosed vs. open-air environment comparisons. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) revealed progressive morphological and intracellular changes in yeast cells following plasma treatment, including localized cell wall thinning and perforation, vacuole enlargement, enhanced vesicle formation, protoplast aggregation, and leakage of intracellular content — consistent with RONS-driven oxidative damage. Optimal treatment parameters balancing antimicrobial efficacy with safety for living tissue were also established, a prerequisite for clinical translation. The study builds on the group’s prior work on plasma sources for biomedical applications and contributes to the growing field of plasma medicine.

Key Highlights:

• Cold microwave plasma jets confirmed effective against S. epidermidis, E. coli, C. acnes, and N. glabratus — organisms spanning bacteria and fungi commonly implicated in wound infection
• RONS — not UV radiation — are the primary inactivation mechanism, confirmed through enclosed/open-air comparisons and colorimetric assays
• TEM analysis reveals progressive yeast cell wall thinning and perforation, vacuole enlargement, vesicle formation, and intracellular content leakage — a detailed ultrastructural map of plasma-induced cell death
• Optimal treatment parameters established balancing antimicrobial efficacy with tissue safety — a critical step toward clinical use
• Dedicated to the memory of co-author František Krčma, who constructed the MW plasma sources and secured funding; he passed away prior to publication
• Relevance: Non-antibiotic wound decontamination technology with growing preclinical evidence base — relevant as antibiotic resistance increasingly complicates chronic wound management

Read full article

Keywords: cold atmospheric plasma, plasma medicine, wound infection antimicrobial, antibiotic resistance wound, wound biofilm, RONS wound healing

Kristína Trebulová Veronika Loupová Barbora Chobotská Lukáš Kletzander Přemysl Menčík Zdenka Kozáková Jan Hrudka Joanna Pawlat Pavel Kulich František Krčma (deceased)

Swift’s AI-powered wound imaging technology shown to improve quality of care and costs to manage complex patients

June 01, 2023 09:00 AM Eastern Daylight Time
TORONTO–(BUSINESS WIRE)–Swift Medical, a digital health technology company focused on improving clinical and economic outcomes in wound care, today announced proven outcomes from more than 20 million wound assessments captured with Swift’s leading, AI-powered wound care platform. Deployed in nearly 4,000 healthcare facilities across North America, Swift’s technology has been shown to speed up wound healing by 37%, reduce wound prevalence and hospitalizations by 35% and 14%, respectively, and reduce hospital length of stay by 62%.

“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system”

Tweet this
“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system,” said Brian Litten, CEO of Swift Medical. “These outcomes demonstrate the impact of having the most powerful wound image dataset in the world and its ability to deliver high quality wound care with reduced costs.”

The Swift Skin & Wound mobile application enables any mobile device to be equipped with AI-powered imaging capabilities to capture clinically validated, high-precision 3D images, measurements, and other clinical data. The imaging captured at the point of care enables real-time, at-risk patient monitoring, proactive decision-making, and remote wound consultations, reducing the time and cost spent evaluating wounds to create a more efficient wound care experience for both clinicians and patients.

Today, more people suffer from chronic wounds than those with breast cancer, colon cancer, lung cancer, and leukemia combined. Despite this costly, growing problem, the current standard of care is outdated and highly inaccurate. Clinicians typically receive less than 10 hours of formal education and rely on paper rulers for measurements and cotton swabs for depth assessment. This inefficient and ineffective approach is both painful for patients and leads to poor diagnostic accuracy, prolonged healing, and inappropriate selection of therapies, putting patients at greater risk for readmission, longer lengths of stay and higher care costs.

With its advanced analytics and proven outcomes, Swift is now poised to partner with health plans and risk-bearing providers to deliver high quality, value-based wound care at scale.

About Swift Medical

Swift Medical is the global leader in digital wound care. We are headquartered in Toronto, with operations expanding across the U.S. and Canada. Our mission is to make empathy-driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,000 healthcare facilities in North America across the continuum of care. Our solutions empower healthcare providers to deliver standardized, accessible and equitable wound care for every patient – with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care. To learn more about Swift Medical, visit us at www.swiftmedical.com.

Contacts
Media

David Mannion
416-303-8020
david.mannion@swiftmedical.com

HCPs’ Attitudes Regarding Current Wound Care Treatments

A recent April 2025 survey published in *Wound Care Today* and sourced from the Journal of Community Nursing asked 789 healthcare professionals (HCPs) about their experiences delivering wound care.

Key Findings:

• Time & Resource Barriers: 69% of respondents identified lack of time and resources as the primary challenge in managing wounds.
• Patient Compliance Issues: 67% noted that non-adherence to treatment regimens complicated their work.
• Access to Advanced Therapies: Nearly half (47%) reported limited access to advanced wound care options.
• Training Gaps: 37% felt they lacked sufficient training, while 32% reported cost pressures as a barrier.
• Overall Satisfaction: Despite frustrations, 63% felt “somewhat satisfied” with their ability to manage wound care.

These insights highlight persistent gaps in infrastructure, patient engagement, and professional development—all critical to enhancing wound healing outcomes.

Keywords:
Wound Care Today,
Journal of Community Nursing,
healthcare professional,
training gaps,
advanced wound therapies,
patient compliance,
resource constraints

Read the full article on Wound Care Today

🔬 Spotlight: Practical Tools to Support Wound Care Professionals

The latest survey of healthcare professionals highlights the urgent need for streamlined education, improved workflow tools, and access to advanced products. These solutions aim to support clinicians in delivering better outcomes while managing real-world constraints:

• Digital Wound Care Platforms: Apps like Tissue Analytics and Swift Medical allow for fast wound documentation, measurement, and photo capture—reducing documentation time and improving care coordination.
• On-Demand Clinical Training: Organizations such as the Wound Healing Society and WOCN Society offer free and low-cost e-learning modules, including case-based wound assessment, dressing selection, and offloading strategies.
• Formulary-Accessible Advanced Dressings: Multi-function products such as Mepilex® Border or Hydrofera Blue READY® simplify care plans and reduce dressing change frequency, helping HCPs manage complex wounds more efficiently.
• Patient Engagement Aids: Tools like visual education sheets, SMS-based adherence reminders, and caregiver training guides have been shown to improve compliance in both acute and chronic wound settings.

By combining point-of-care tech, evidence-based education, and patient-facing support tools, wound care teams can overcome many of the systemic and day-to-day barriers identified in recent surveys.

Periwound Skin: Understanding and Managing the Skin Surrounding Wounds

Proper care of the periwound skin—the area extending approximately 1.5 inches from the wound edge—is essential for effective wound healing. This delicate skin is susceptible to damage from moisture, adhesives, and infection, which can impede the healing process. Read the full article.

Key Highlights:

• Moisture-Associated Skin Damage (MASD): Excessive wound exudate can lead to maceration, causing redness, irritation, and pain in the periwound area. Managing moisture levels is crucial to prevent skin breakdown.
• Medical Adhesive-Related Skin Injury (MARSI): Improper application or removal of wound dressings can strip the skin, leading to MARSI. Over 25% of post-surgical patients experience MARSI in the periwound region.
• Signs of Periwound Complications: Indicators include induration (hardening), erythema (redness), swelling, bruising, red streaks emanating from the wound, fever, or general malaise.
• Prevention Strategies:
  • Gently clean the periwound area during each dressing change.
  • Use barrier creams like petroleum jelly to protect against moisture.
  • Minimize dressing changes to those recommended by healthcare providers.
  • Carefully remove adhesives by pressing down on the skin beneath to reduce trauma.
  • Regularly assess the periwound area for any changes or signs of damage.
• Treatment Approaches: Addressing periwound skin damage involves preventing further injury and promoting healing. This may include repositioning bandages, using barrier creams, and consulting healthcare providers for tailored care plans.

Maintaining the integrity of the periwound skin is vital for optimal wound healing. Incorporating periwound care into the overall wound management plan can enhance patient outcomes and reduce complications.

Read the full article on the Verywell Health website.

Keywords:
periwound skin,
moisture-associated skin damage,
medical adhesive-related skin injury,
wound healing,
barrier creams

Jingfang Granules Accelerate Diabetic Wound Healing via Multi‑Target Pathways

A recent manuscript in *Drug Design, Development and Therapy* reveals that Jingfang Granules (JFG), a traditional Chinese medicine blend of 11 herbs, significantly promotes healing of diabetic wounds in preclinical models. The study, using network pharmacology, molecular docking, and animal experiments, explores the mechanisms behind its efficacy.

Key Highlights:

• Multi-Mechanism Action: JFG alleviates oxidative stress, suppresses inflammation, promotes angiogenesis, and normalizes glucose and lipid metabolism—key processes impaired in diabetic wound healing.
• Strong Preclinical Results: In STZ-induced diabetic rats, JFG (1–2 g/kg) enhanced wound closure: day 8 closure improved from ~62% (untreated) to ~70–73%, and by day 14 reached ~95–96% vs 88% in controls.
• Phytochemical Targets Identified: Serum analysis found 56 active compounds. Network mapping highlighted six core protein targets—AKT1, EGFR, MAPK3, MAPK1, IL6, TNF—suggesting modulation of PI3K‑AKT and MAPK pathways.
• In Vitro Validation: JFG serum preparations protected endothelial (H₂O₂/glucose damage) and keratinocyte cultures; it reduced inflammatory cytokines and enhanced angiogenic behaviors.

By integrating computational and experimental data, this study provides compelling preclinical evidence that Jingfang Granules can effectively support diabetic wound healing through multi-dimensional molecular mechanisms.

Read the full study in Drug Design, Development and Therapy.

Keywords:
Jingfang Granules,
network pharmacology,
PI3K‑AKT pathway,
MAPK pathway,
diabetic wound healing

Advances in Burn Wound Management: Innovative Strategies for Healing and Infection Control

A recent literature review published in Wounds explores the latest developments in burn wound management, emphasizing innovative strategies that enhance healing and infection control. The article provides a comprehensive overview of burn wound causes, classifications, and treatments, discussing the healing phases, potential infections, and complexities associated with conventional treatments. It also highlights advanced techniques that have proven effective in reducing hospital stays and making treatment more cost-effective.

Key Highlights:

• Advanced Therapies: The review discusses the use of adipose tissue-derived stem cells (ADSCs), bone marrow-derived stem cells (BMSCs), and umbilical cord-derived stem cells (UDSCs) in promoting burn wound healing.
• Innovative Materials: The application of acellular fish skin (AFS) and extracellular matrix (ECM) components are highlighted as effective in supporting tissue regeneration and reducing inflammation.
• Modern Techniques: The utilization of negative pressure wound therapy (NPWT) and platelet-derived growth factor (PDGF) are examined for their roles in enhancing wound healing and minimizing infection risks.

These advancements in burn wound management represent significant progress in the field, offering new avenues for treatment that prioritize patient outcomes and cost-effectiveness. By integrating these innovative strategies into clinical practice, healthcare providers can improve healing times, reduce complications, and enhance the overall quality of care for burn patients.

Read the full article on the HMP Global Learning Network website.

Keywords:
burn wound management,
stem cell therapy,
negative pressure wound therapy

Advanced Small Extracellular Vesicles Delivery Systems for In Situ Tissue Engineering

Summary: Published March 12, 2026 in Extracellular Vesicles and Circulating Nucleic Acids (OAE Publishing, Vol. 7, pp. 354–376), this comprehensive review from Peking University School and Hospital of Stomatology and Peking University Third Hospital systematically covers the state of the art in small extracellular vesicle (sEV) delivery systems for in situ tissue engineering — an approach that activates the body’s innate regenerative capacity by implanting bioactive materials rather than transplanting pre-constructed grafts. sEVs (30–150 nm diameter) are natural nanovesicles secreted by virtually all cell types, carrying lipids, proteins, DNA, RNA, and microRNAs that mediate intercellular communication and regulate immune responses, angiogenesis, and tissue regeneration. Their key advantages — low immunogenicity, multi-target regulatory capability, and ability to cross biological barriers — make them promising cell-free alternatives in regenerative medicine. However, their therapeutic efficacy is dose-dependent and their rapid clearance by the mononuclear phagocyte system (liver, spleen, kidneys) when administered systemically or locally limits therapeutic sustainability. The review covers sEVs derived from mesenchymal stem cells (BMSCs, ADSCs, DPSCs), immune cells, endothelial cells, body fluids (platelet-rich plasma, milk), and plant-derived vesicle-like nanoparticles (PELNs from ginger, ginseng, purslane). For delivery systems, it categorises scaffold-based approaches (physical adsorption onto 3D-printed PLA, β-TCP, PLGA, PCL, titanium, and hydroxyapatite scaffolds; affinity coating using polydopamine, PEI, heparin, tannic acid, and calcium phosphate) and hydrogel-based approaches (direct physical entrapment in silk fibroin, GelMA, chitosan/ZnO, PEG hydrogels; chemical immobilisation via carbodiimide crosslinkers or CP05 fusion peptides targeting CD63). Applications in wound healing include ADSC-sEV acceleration of diabetic wound repair, HUVEC-sEV promotion of angiogenesis, microneedle patch delivery in diabetic wound models, and CP05-mediated sEV anchoring to hydrogels for granulation tissue formation. Future directions discussed include long-term sustained release systems and environmentally responsive (pH-, temperature-, enzyme-triggered) release platforms.

Key Highlights:

• sEV sources compared: MSC-derived (BMSC, ADSC, DPSC) for bone, immune, and wound healing; HUVEC-derived for angiogenesis; platelet-rich plasma for anti-inflammatory and pro-angiogenic effects; plant-derived PELNs for anti-inflammatory and gut microbiota modulation
• Scaffold delivery strategies: physical adsorption (simple but burst-releasing) vs. affinity coating using polydopamine, PEI, calcium phosphate — PDA and biomineralised scaffolds enable sustained sEV release for up to 21 days
• Hydrogel strategies: direct encapsulation (silk fibroin, GelMA, chitosan/ZnO-NPs for diabetic wound dressings) vs. covalent immobilisation via CP05 fusion peptides targeting CD63 on sEV surface — enables more sustained, controlled retention at wound site
• Wound healing applications: ADSC-sEVs regulate Keap1/Nrf2 axis in diabetic wound fibroblasts; HUVEC-sEVs combined with tazarotene accelerate cell proliferation and tube formation; microneedle-MOF platforms deliver antimicrobial effect plus sEV-mediated tissue repair
• Responsive release: hydrogel-embedded sEVs can be engineered for pH-, temperature-, enzyme-, and electrical-responsive release — aligning drug delivery with the dynamic phases of wound healing (inflammation, proliferation, remodelling)
• Key challenges: large-scale sEV production yield, standardisation of preparations, long-term release kinetics optimisation, and clinical translation from preclinical models to human trials

Read full article

Keywords: extracellular vesicles wound healing, exosome wound care, sEV diabetic wound healing, hydrogel wound dressing drug delivery, in situ tissue engineering wound, stem cell exosome angiogenesis

Yike Gao, Jingyi Sang, Yuming Zhao, Yue Wang, Zuoying Yuan

Reflecting on AI in Wound Care: Insights from SAWC Spring Keynote

Dr. Eric Lullove’s keynote address at the Spring 2025 Symposium on Advanced Wound Care (SAWC) in Grapevine, Texas, titled “Healing with Intelligence,” spotlighted the evolving role of artificial intelligence (AI) in wound management. His talk encouraged clinicians to view AI as an ally—not a replacement—in delivering better outcomes and streamlining care.

Key Themes:

• From Reactive to Predictive: AI tools are helping clinicians shift from reactive wound care to data-driven, anticipatory decision-making.
• Clinical Support, Not Substitution: Dr. Lullove emphasized that AI should support—not replace—clinical judgment by reducing administrative burdens and improving diagnostics.
• Workforce Reinforcement: With a growing patient load and clinician shortages, AI offers scalable tools to manage time, triage effectively, and prioritize care intensity.
• Awareness Gaps: A live poll revealed that 70% of attendees were unfamiliar with AI’s current role in wound care, highlighting the urgent need for education and integration training.
• Ethical & Practical Concerns: Speakers warned about algorithmic bias, data security, and the need for real-world validation before widespread adoption.
• Patient Engagement: AI-driven visualizations and adherence tracking can empower patients—bridging the gap between clinic and home care.
• Call for Collaboration: The keynote ended with a challenge for clinicians, researchers, and technology companies to work together in shaping an ethical, equitable, and scalable AI future in wound care.

As AI tools continue evolving, the wound care community is urged to take the lead in guiding responsible implementation—ensuring that human-centered care remains at the heart of digital transformation.

Keywords:
AI wound care,
clinical decision support,
SAWC 2025,
wound care innovation,
digital health

Watch the full video on HMP Global Learning Network

🔬 Spotlight: AI-Enabled Tools Transforming Wound Care

Artificial intelligence is reshaping wound care workflows—from triage to treatment planning—by offering scalable support across clinical and home settings. These tools exemplify the next wave of innovation:

• SmartWound® AI: A mobile imaging app that uses machine learning to assess wound dimensions, tissue types, and healing trajectory, enabling consistent documentation and decision support.
• Thermal Texture Platforms: Non-contact systems like those used in diabetic foot ulcer surveillance apply thermal image analysis and pixel mapping to predict healing outcomes and flag high-risk wounds early.
• Remote Wound Monitoring Apps: Tools like Tissue Analytics® or Swift® allow patients or home health workers to capture and securely transmit wound photos, supported by AI-driven alerts for deterioration or improvement.
• AI Documentation Assistants: Integrated into EHRs, these tools reduce clinician burden by auto-populating structured wound assessments and prompting evidence-based interventions.

As AI adoption grows, these platforms can help bridge care gaps, support earlier intervention, and preserve clinical bandwidth—especially in settings facing provider shortages.

$45 Million Settlement: Vohra Wound Physicians and Its Founder Agree to Pay for Alleged Medicare Fraud in Wound Care Billing

November 25, 2025 – The U.S. Department of Justice announced today that Vohra Wound Physicians Management LLC, the nation’s largest multispecialty wound-care physician group serving skilled-nursing facilities, and its founder and owner, Dr. Ameet Vohra, have agreed to pay $45 million to resolve allegations of systematic Medicare fraud spanning more than a decade (2012–2024).

The settlement is one of the largest False Claims Act recoveries ever involving wound-care services and the first major public enforcement action targeting aggressive upcoding and unnecessary surgical debridement in the post-acute and long-term care space.

Core Allegations (as outlined in the DOJ settlement agreement)

1. Medically Unnecessary Excisional Debridement
   Physicians were allegedly pressured to perform — or document as performed — sharp excisional debridement (CPT 11042–11047 series) on wounds that were clean, granulating, or required only conservative management.
2. Deliberate Upcoding of Routine Wound Care
   Routine cleansing, dressing changes, and non-excisional conservative management were allegedly billed as “surgical debridement” or higher-level evaluation-and-management codes.
3. Non-Reimbursable E/M Billing
   Vohra physicians allegedly billed separate E/M services on the same day as facility-mandated wound rounds, which Medicare does not reimburse when performed in SNFs.
4. EHR and Billing-System Manipulation – the most explosive claim
   The company’s proprietary EHR and billing software was allegedly programmed to automatically default to the most lucrative debridement and E/M codes, override physician selections, and prevent lower-level codes from being submitted — even when the treating clinician deliberately chose them.
5. Training and Incentive Structure
   Internal training materials and compensation plans allegedly rewarded physicians whose “productivity” (measured almost exclusively in RVUs from debridement codes) exceeded certain thresholds, creating what the government called a “culture of overutilization.”

Settlement Breakdown and Corporate Integrity Agreement

• Civil settlement: $45,000,000
• Five-year Corporate Integrity Agreement (CIA) with mandatory independent audits, annual risk assessments, EHR transparency requirements, and physician-level billing monitoring
• No admission of liability (standard in most FCA settlements)
• Ability-to-pay analysis was not cited, indicating the company had sufficient liquidity to pay the full amount

Why This Case Matters to the Entire Wound-Care Ecosystem

1. Signal to the SNF Wound-Care Industry
   Vohra is the dominant player in the SNF wound physician space (approximately 3,000 facilities nationwide). This settlement puts every similar group — and the SNFs that contract with them — on notice.
2. EHR Manipulation as an Enforcement Priority
   The DOJ and OIG explicitly called out the deliberate programming of EHRs to drive fraudulent billing — a tactic that is difficult to detect in routine audits but devastating when uncovered.
3. Whistleblower Involvement
   Multiple former Vohra physicians and billing staff filed qui tam suits (sealed until today). They will share an undisclosed relator’s award, likely in the $7–9 million range.
4. Ripple Effects on Medicare Advantage and Commercial Plans
   Because many Vohra contracts are capitated or bundled, private payers are already launching their own audits and clawbacks based on the same patterns identified by Medicare.
5. Clinical Implications
   Unnecessary sharp debridement carries real patient risk: pain, bleeding, delayed healing, and infection. Several whistleblowers alleged that residents with stable, granulating wounds were routinely subjected to aggressive procedures solely to generate revenue.

Industry Reaction (early statements as of Nov 25, 2025)

• Alliance for Wound Care Stakeholders: “We support appropriate enforcement but are concerned that legitimate, evidence-based debridement will now be second-guessed.”
• American Professional Wound Care Association (APWCA): Issued a call for clearer CMS guidance on excisional vs selective debridement documentation.
• Major SNF chains (Genesis, Ensign, ProMedica): Declined comment or stated they are “reviewing contracts and internal audits.”

What Happens Next

• Expect a wave of OIG and Medicare contractor (MAC/UPIC) audits targeting debridement claims in SNFs nationwide.
• EHR vendors serving the wound space are likely to face subpoenas regarding default settings and hard-coded billing rules.
• Private whistleblower suits against other large wound-physician groups have already been filed under seal.

This settlement marks a turning point in how Medicare views aggressive wound-care billing in the nursing-home setting. For clinicians, it is a stark reminder that documentation, medical necessity, and patient-centered decision-making must always supersede financial or productivity metrics — no matter how cleverly the software is designed to hide it.

Sources
U.S. Department of Justice – Office of Public Affairs (Nov 25, 2025)
Settlement Agreement and Corporate Integrity Agreement (publicly available on OIG website)
Multiple sealed qui tam complaints unsealed today in the Eastern District of Texas and Southern District of Florida

Stay tuned — this story is far from over.

Summary: The Wound Care Today Learning Zone hosts a dedicated CPD e-learning module on the Debrisoft family of monofilament fibre debridement devices, produced in partnership with Lohmann & Rauscher (L&R), the manufacturer of the Debrisoft product range. The module covers the main features and benefits of Debrisoft Pads and the Debrisoft Lolly (a monofilament fibre pad with an ergonomic handle for hard-to-reach wounds), and provides guidance on correct use. Debrisoft’s monofilament fibre technology works by physically disrupting and lifting devitalised tissue, slough, biofilm, fibrinous deposits, and debris from wound beds and periwound skin through circular or sweeping motion, with the device hydrated with saline or wound cleanser prior to application. The technology received a positive recommendation from the National Institute for Health and Care Excellence (NICE Medical Technology Guidance MTG17) for use in acute and chronic wounds in community and clinic settings, based on clinical evidence of rapid and effective mechanical debridement with minimal patient discomfort and demonstrated cost savings versus saline/gauze, hydrogel, and larval therapy. Key supporting evidence includes: a 2021 prescribing audit by Burnett et al. (J Wound Care 30(5):381–388, DOI: 10.12968/jowc.2021.30.5.381) in 486 NHS patients showing reduced wound-care prescribing costs following Debrisoft introduction; a 2018 multicenter user test by Dissemond et al. (J Wound Care 27(7):421–425) across 155 wounds evaluating the Debrisoft Lolly for hard-to-reach wound debridement; and a 2018 ex vivo and clinical study by Schultz et al. (J Wound Care 27(2):80–90) demonstrating effectiveness at removing biofilm and slough. The Debrisoft Duo product extends the original Pad with a dual-sided design: the original soft white monofilament side for debris, exudate, and biofilm removal, and a textured beige side for loosening firmly adherent fibrinous slough. The module is freely accessible to registered Wound Care Today users and offers CPD certification upon completion.

Key Highlights:

• Monofilament technology: Debrisoft’s densely packed monofilament fibres reach into the wound bed and periwound skin to physically disrupt and remove necrotic tissue, biofilm, fibrinous slough, dry skin, and keratosis — while sparing newly formed granulation tissue and epithelial cells
• NICE MTG17 endorsement: the only mechanical debridement technology to receive NICE Medical Technology Guidance for community use; cost-saving analysis showed £77–£222 savings vs. hydrogel, £97–£347 vs. saline/gauze, and £180–£484 vs. larval therapy per patient
• Debrisoft Lolly: ergonomic handle design for debridement of cavities, sinuses, tunnelling wounds, body folds, and other anatomically challenging wound locations — evaluated in 155 wounds across 20 international centres by Dissemond et al.
• Biofilm relevance: Schultz et al. (2018) demonstrated ex vivo removal of mature biofilm from porcine dermal tissue, supporting Debrisoft’s role within biofilm-based wound care (BBWC) and wound bed preparation (TIME/TIMERS framework)
• Prescribing impact: Burnett et al. (2021) NHS audit of 486 patients found that introduction of Debrisoft monofilament debridement pad was associated with measurable reductions in wound-care prescribing costs over 6 months — providing real-world economic evidence beyond the NICE modelling
• Module access: freely available after registration at woundcare-today.com/learning-zone; CPD certification awarded on completion — suitable for district nurses, tissue viability nurses, and wound care clinicians seeking structured learning on mechanical debridement tools

Access module

Keywords: Debrisoft wound debridement, monofilament debridement pad, wound bed preparation debridement, NICE wound debridement guidance, biofilm mechanical debridement, CPD wound care education

Wound Care Today / Lohmann & Rauscher